Research programme: antisense oligonucleotide MDM2 - Idera Pharmaceuticals

Drug Profile

Research programme: antisense oligonucleotide MDM2 - Idera Pharmaceuticals

Alternative Names: GEM 240; HDMAS5; Research programme: anti-MDM2 antisense oligonucleotides

Latest Information Update: 20 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Idera Pharmaceuticals; Johns Hopkins University; University of Alabama
  • Developer Genzyme Corporation; Idera Pharmaceuticals; University of Alabama
  • Class Antineoplastics; Nucleotides
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 31 Mar 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 13 Sep 2005 Hybridon is now called Idera Pharmaceuticals
  • 05 Mar 2004 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top